Medical device company Teleflex has introduced ARROW JACC (jugular axillo-subclavian central catheter), a small-french size antimicrobial and antithrombogenic catheter designed for both acute and long-term use, with Chlorag+ard technology.
The Chlorag+ard technology in ARROW JACC helps fight against thrombosis and infection for around 30 days and is effective against the full spectrum of bacterial and fungal pathogens.
The ARROW JACC, which is designed for the vascular access specialist, had received the US Food and Drug Administration approval in November 2012.
Teleflex chairman president and CEO Benson Smith noted the company is very excited to announce its launch of the ARROW JACC with Chlorag+ard technology.
"This product’s innovative design offers clinicians a new and unique treatment option that further demonstrates our commitment to achieve ‘Zero Complications’ in vascular access.
"We believe the ARROW JACC represents a significant step forward in raising the standard of care for patients requiring vascular access, while equally addressing the clinical need for treatment efficiency and cost-effectiveness in our challenging healthcare environment," Smith added.
Teleflex and its ARROW vascular division helped clinicians expand their scope of practice to include central venous catheter insertion in more than 40 states till date.